EBV persistence without its EBNA3A and 3C oncogenes in vivo

Anita Murer, Donal McHugh, Nicole Caduff, Jens Kalchschmidt, Mario Barros, Andrea Zbinden, Riccarda Capaul, Gerald Niedobitek, Martin Allday, Obinna Chijioke, Christian Münz

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


The oncogenic Epstein Barr virus (EBV) infects the majority of the human population and usually persists within its host for life without symptoms. The EBV oncoproteins nuclear antigen 3A (EBNA3A) and 3C (EBNA3C) are required for B cell transformation in vitro and are expressed in EBV associated immunoblastic lymphomas in vivo. In order to address the necessity of EBNA3A and EBNA3C for persistent EBV infection in vivo, we infected NOD-scid γc nullmice with reconstituted human immune system components (huNSG mice) with recombinant EBV mutants devoid of EBNA3A or EBNA3C expression. These EBV mutants established latent infection in secondary lymphoid organs of infected huNSG mice for at least 3 months, but did not cause tumor formation. Low level viral persistence in the absence of EBNA3A or EBNA3C seemed to be supported primarily by proliferation with the expression of early latent EBV gene products transitioning into absent viral protein expression without elevated lytic replication. In vitro, EBNA3A and EBNA3C deficient EBV infected B cells could be rescued from apoptosis through CD40 stimulation, mimicking T cell help in secondary lymphoid tissues. Thus, even in the absence of the oncogenes EBNA3A and 3C, EBV can access a latent gene expression pattern that is reminiscent of EBV persistence in healthy virus carriers without prior expression of its whole growth transforming program.

Original languageEnglish
Article numbere1007039
JournalPLoS Pathogens
Issue number4
StatePublished - Apr 2018
Externally publishedYes


Dive into the research topics of 'EBV persistence without its EBNA3A and 3C oncogenes in vivo'. Together they form a unique fingerprint.

Cite this